Connect with us

Technology

Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

Published

on

SHANGHAI, Feb. 17, 2025 /PRNewswire/ — Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independent research and external collaborations, thereby driving transformation and development in the pharmaceutical industry through technological advancements. At the same time, Fosun Pharma is accelerating the deeper application of AI technology in marketing, customer service, and smart office solutions, using AI to improve quality and efficiency while promoting enhanced corporate management effectiveness.

Self-developed PharmAID Decision Intelligence Platform Integrates Global Leading Large Model Technology and Has connected with Deepseek R1

As a pioneer in the AI transformation of the pharmaceutical industry, Fosun Pharma recently launched its self-developed PharmAID decision intelligence platform internally. This platform establishes a full lifecycle intelligent decision-making network covering innovative R&D scenarios. Deeply integrated with global leading large model technologies, the platform has taken the lead in connecting to with Deepseek R1. Based on the PharmAID decision intelligence platform, Fosun Pharma is accelerating the development of “drug commercial value-assisted decision-making” capabilities, broadening decision-making perspectives, and improving decision accuracy. The platform enhances drug R&D efficiency and accelerates the transformation of R&D achievements by integrating point prediction, conformational prediction, binding mechanism analysis, toxicology optimization, medical writing, and clinical information extraction. This initiative aims to lead innovation and transformation, and it is the first self-developed AI decision intelligence platform in pharmaceutical industry.

The PharmAID decision intelligence platform offers AI translation and AI medical writing/revision features, significantly improving information retrieval and writing efficiency under the support of AI technology. At present, the PharmAID decision intelligence platform has integrated multiple professional clinical information and pipeline data platforms around the world, increasing content generation accuracy in the pharmaceutical and healthcare field by 50% compared to general large models, with data updated at T+1, ensuring outstanding accuracy and timeliness. Moreover, Fosun Pharma applies AI technology to carry out intelligent training for sales personnel and further assists business scenarios, achieving “more precise” marketing. Through the deep empowerment of the PharmAID decision intelligence platform, Fosun Pharma is building its digital competitiveness, leading the entire pharmaceutical industry into a new era of AI-driven innovation.

AI Technology Empowers Innovative R&D and Accelerate Breakthroughs

Fosun Pharma actively promotes AI-driven innovation. As early as 2022, Fosun Pharma formed a strategic partnership with AI pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug R&D, aiming to integrate AI with physical modeling to jointly advance new drug development processes. This collaboration leverages DP Technology’s technical strength and project experience in the “AI for Science” field, combining expertise in drug discovery and AI computing to provide new insights for the development of biologics antibodies/ADCs and small molecule drugs targeting difficult-to-drug targets.

Building an “AI+X” Smart Healthcare Ecosystem

In medical devices sector, Fosun Aitrox, a subsidiary of Fosun Pharma, focuses on the medical AI field and is one of the few companies in China offering comprehensive AI medical service solutions across multiple departments including radiology, pathology, ultrasound, cardiology, respiratory, orthopedics, neurology, and thyroid and breast surgery. Fosun Aitrox delves into medical institutions and primary healthcare service scenarios, identifying real needs and enhancing service capabilities in core scenarios of tiered healthcare systems, including early screening, remote diagnosis, and precision medicine. Through the “AI+X” model, Fosun Aitrox collaborates deeply with top medical centers, promoting the transformation of scientific research achievements and the popularization of standardized medical systems, empowering the construction of smart diagnosis and treatment systems. Its three major AI-assisted diagnostic product lines—radiology imaging, pathology imaging, and ultrasound imaging—have been widely used clinically and have won multiple world championships in international competitions.

Fosun Aitrox’s AI medical imaging products can quickly and accurately analyze medical imaging data, providing doctors with diagnostic suggestions, helping them more efficiently identify lesions and assess conditions, thereby improving diagnostic accuracy and timeliness. The application of this technology not only enhances the quality and efficiency of medical services but also benefits patients in remote and resource-scarce areas, allowing them to access high-quality medical services locally. To date, Fosun Aitrox has expanded its presence to cover 70% of China, with operating businesses in over 20 provinces, establishing nearly 10 regional smart healthcare project models. The company has released and is developing more than 70 AI products.

Additionally, Fosun Pharma’s incubated company, JeDiCare, leverages its extensive experience in image navigation algorithm development and interventional consumable design, along with a global perspective, to innovatively introduce AR navigation technology into minimally invasive surgery. Its self-developed puncture surgery navigation device (AR navigation puncture positioning system) is currently under market application review. This product features proprietary “monocular vision augmented reality” technology, integrating computer vision monocular tracking and AR display technology, not only achieving precise positioning but also optimizing the positioning process. In the future, with the assistance of the AR navigation puncture positioning system, primary hospitals will also be able to perform precise thoracoscopic surgeries, bringing high-quality medical care to more patients.

Looking ahead, Fosun Pharma will continue to increase investment and exploration in AI, accelerating the construction of AI innovation across the entire industry chain through independent research and external collaborations, leading the AI transformation of the pharmaceutical industry, and contributing more wisdom and strength to the cause of human health.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit our official website: www.fosunpharma.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fosun-pharmaceutical-deeply-embraces-ai-self-developed-pharmaid-decision-intelligence-platform-boosts-efficient-innovation-302377891.html

SOURCE Fosun Pharma

Continue Reading

Technology

From Pasture to Power: Gordon Solar Farm Showcases the Future of Farming and Solar Energy in New Zealand

Published

on

By

WHAKATĀNE, New Zealand, Nov. 10, 2026 /PRNewswire/ — An agrivoltaic project in Galatea, New Zealand, is demonstrating how agricultural land can generate renewable energy while continuing to support productive farming, offering a new approach to land use for rural communities.

The Gordon Cattle and Solar Farm, located in the Whakatāne District, combines a 4.7 MW solar installation on 8 hectares of land with a dairy farm operation of around 700 cattle heads. Featuring TCL Solar 625W TOPCon modules and Clenergy ezTrackers D1P, the project brings together solar technology, agricultural expertise and tracking infrastructure to demonstrate the potential of dual-purpose land use.

The official opening of the project will take place on Thursday, 12 November 2026, at the Gordon Dairy Farm in Galatea. The public event will bring together representatives from the agricultural and renewable energy industries, project partners and local communities, with a live panel discussion exploring the opportunities and practical considerations of integrating solar generation into working farmland.

Making More of Agricultural Land

Agrivoltaics refers to the integration of solar energy generation and agricultural activities on the same land. At the Gordon Solar Farm, solar trackers are elevated to 2.2 metres, allowing cattle to continue grazing beneath the installation. During daylight hours, the tracking system follows the sun to optimise electricity generation, while the farm retains its agricultural function.

This approach offers potential benefits beyond electricity production. By providing shade, the solar installation reduces direct sun exposure to the ground, lowering soil temperatures and moisture loss, and diminishing irrigation requirements. For livestock, shaded areas can offer relief from intense heat and contribute to improved animal comfort during warmer conditions.

The relationship can also benefit the solar installation itself. Vegetation and moisture beneath the panels may help moderate the module temperature and support energy generation.

Solar Technology Designed for Agricultural Environments

Operating solar modules in an agricultural setting presents specific technical challenges. One consideration is exposure to ammonia, a corrosive gas released through livestock waste, manure and agricultural processes. Over time, ammonia can affect susceptible materials and components within solar modules, potentially contributing to corrosion and reduced long-term performance.

This makes module durability an important consideration when selecting solar technology. The TCL Solar TOPCon modules supplied for the Gordon project have undergone ammonia corrosion resistance testing in accordance with IEC 62716, the international standard for assessing resistance to ammonia exposure.

The enhanced certification provides an additional layer of validation and reflects the importance of selecting technology suited to the specific environment of a project.

Bringing Farming and Solar Expertise Together

The Gordon Solar Farm has been delivered through collaboration between the Gordon family, TCL Solar, Clenergy, Micropico, insurance and financial partners. Each partner brings a different perspective to the project, from the practical realities of operating a working dairy farm to the engineering and technology required to integrate solar generation into an agricultural environment.

These perspectives will come together at the official opening during a live panel discussion that will explore the lessons emerging from the project and consider a broader question for the agricultural and energy sectors: how can landowners create additional value from their land while continuing to support the farming businesses and communities that depend on it?

A Model for the Future of Rural Renewable Energy

For TCL Solar, the project demonstrates the importance of reliable module technology in installations with specific operational and environmental demands.

As New Zealand continues to expand its renewable energy capacity, the Gordon Solar Farm offers a practical example of how solar energy can become part of the wider agricultural landscape, creating opportunities for farmers, energy providers and rural communities alike.

The official opening of the Gordon Cattle and Solar Farm will take place on Thursday, 12 November 2026, at 228 Grant Road, Galatea, New Zealand.

For more information, visit www.tclsolar.com

About TCL Solar

TCL Solar is one of TCL Zhonghuan’s two flagship module brands, alongside SunPower for the Australian and Pacific markets.

TCL Zhonghuan (TCL Zhonghuan Renewable Energy Technology Co., Ltd.) is a BNEF Tier 1 global solar manufacturer and a technology leader across the photovoltaic value chain. Founded in 1958, the company has played a defining role in the development of the global PV industry, beginning monocrystalline silicon R&D in 1969. With full vertical integration from ingots and wafers through to modules, TCL Zhonghuan became the world’s #1 silicon wafer manufacturer in 2024, achieving 19% of global production capacity share. Ongoing innovation is supported by over 4,600 solar-specific patents, alongside advanced manufacturing capabilities. The acquisition of SunPower in 2025 and DAS Solar in 2026 further strengthens TCL Zhonghuan’s position in high-efficiency BC technology.

View original content:https://www.prnewswire.com/apac/news-releases/from-pasture-to-power-gordon-solar-farm-showcases-the-future-of-farming-and-solar-energy-in-new-zealand-302934622.html

SOURCE TCL Solar

Continue Reading

Technology

GTN appoints former Gemini and Kraken executive Mark Jennings as global head of digital assets

Published

on

By

New role to lead GTN’s tokenisation strategy as more platforms bring traditional assets on-chain

DUBAI, UAE, Nov. 10, 2026 /PRNewswire/ — GTN, the global fintech powering limitless investment, today announced the appointment of Mark Jennings as global head of digital assets. Mark will lead GTN’s strategy to support tokenised securities through its global market access.

Mark joins GTN from Gemini, where, as CEO of Gemini Europe, he led the exchange’s European expansion. Before that, he held senior roles at Kraken, including CEO of Crypto Facilities, its FCA-regulated derivatives venue for institutional clients.

Manjula Jayasinghe, GTN’s co-founder and group CEO, said: ‘We are seeing growing demand for tokenised securities, where investors can trade traditional assets on-chain, 24/7, with real-time settlement, and we expect this trend to accelerate in the years ahead. With our industry-leading multi-market, multi-asset coverage, we are well positioned to help platforms bridge traditional and digital markets. Mark brings substantial experience from the digital assets industry and will lead our efforts with the right technology, partnerships and regulatory approach.’

Mark said: ‘Tokenisation is one of the most significant shifts in market infrastructure in decades. At Gemini and Kraken, I saw first-hand users’ demand for traditional assets alongside crypto, and the complexity of delivering them in a robust, compliant and scalable way. GTN has already done the difficult work to connect to markets and asset classes. That puts us in a unique position to take a leading role in helping platforms bring those assets on-chain. I’m excited to lead that work with platforms across the ecosystem to bring tokenised securities to their users.’

Mark’s appointment follows GTN’s hire of former Saxo Bank executive Daniel Endler as its first group chief product officer in October. Together, the two appointments strengthen GTN’s senior leadership as it expands its offering for financial institutions and digital asset platforms.

About GTN
GTN is the global fintech infrastructure powering limitless investment through a unified API-first architecture. By combining cloud-native technology with deep institutional expertise, GTN provides brokers, banks, asset managers and fintechs with brokerage infrastructure spanning 90+ markets and up to 8 asset classes across GTN’s six regulated entities, through a single API, enabling partners to create the next generation of investing and trading experiences. From fractional trading and micro-portfolios, including $1 fractional bonds, to full-service brokerage, GTN automates the investment lifecycle from digital onboarding to post-trade settlement. As a single counterparty, GTN reduces technical and regulatory burdens, enabling investment banks, brokerage firms and wealth management firms to scale without having to build technology from scratch.

GTN has over 700 professionals across 14 countries and serves more than 500 clients worldwide, united by one mission: transforming the accessibility of investment and trading opportunities. GTN operates through six regulated entities, each authorised in its own jurisdiction: FCA in the UK, DFSA in the DIFC, MAS in Singapore, SEC and FINRA in the US, FSCA in South Africa and SFC in Hong Kong. Strategic investors include IFC (World Bank Group) and SBI Ventures Singapore. To learn more, visit www.gtngroup.com or follow us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/gtn-appoints-former-gemini-and-kraken-executive-mark-jennings-as-global-head-of-digital-assets-302933671.html

SOURCE GTN

Continue Reading

Technology

AI Plans Outrun Store Realities as Bad Stock Data Can Cost Large Retailers Millions Each Year

Published

on

By

Scandit survey of store associates finds stock records match shelves less than half the time, fueling a ‘shadow store’ of paper, chats and photos that leaves AI working from an incomplete view of the store and business

ZÜRICH, Nov. 10, 2026 /PRNewswire/ — Scandit, the leader in smart data capture powered by vision AI, today released the results of global research revealing that retail’s race to deploy AI is running ahead of the data reality inside its stores. Store associates reported that stock information matches what they find on the shelf just 46% of the time while only 8% trust store data completely. This creates a costly gap between what the system says, what is actually in the store and what customers experience, while leaving AI and other technology investments to act on incomplete records.

That gap is already being absorbed by labor. Associates estimate they would each get back more than 4.4 hours a week, nearly six working weeks a year, if they had data they could trust. That time amounts to millions in recoverable labor hours. A retailer employing 10,000 store associates, for example, faces more than $41 million a year* in labor cost tied to compensating for the gap. Extrapolating that time across the entire pool of retail associates in the U.S., as tabulated by the U.S. Bureau of Labor Statistics, inaccurate data could cost the retail industry as much as $22 billion annually.

And when the system is wrong, associates do what they have to do to keep the store running. Nearly half (49%) correct the record themselves and 44% raise a stock adjustment. But among associates who take action, 42% bypass the official system entirely, while 68% use at least one informal method, including paper notes, team chats, personal phone photos and apps or memory. The result is a ‘shadow store’ in which vital information exists outside the record that head office, dashboards and AI systems rely on.

“Retailers do not have an AI adoption problem as much as a store truth problem,” said Samuel Mueller, CEO and co-founder of Scandit. “Associates are spending valuable time repairing these gaps, yet much of that work disappears into unofficial tracking systems. Before retailers ask AI to make more decisions based on inaccurate store data, they need a shared, accurate view of what is actually happening on the shelf and across their stores.”

Associates’ trust in stock data does not build gradually. The survey highlights it stays low until the data is very good. Only 8% of associates completely trust their store’s stock information, and only one in four say it is accurate more than 70% of the time. Among associates who put accuracy anywhere up to 50%, roughly a quarter report high trust, and that figure barely moves until accuracy passes 70%, when it rises sharply.

“This is not a gradual improvement problem,” said Andrew Smith, Managing Partner and co-founder of ThinkUncommon and a RETHINK Retail Top Expert since 2021. “Moving stock accuracy from 46% to 60% may look like progress in a board report and still change nothing on the floor. Trust only begins to move once accuracy clears 70%, and until then associates do what sensible people do: they check the shelf themselves and either correct the system or just do what they need to do to help the customer in front of them.”

The consequences extend beyond productivity. Associates report spending an average of 4.1 hours each week handling customer questions that store technology should be able to answer, and are asked to physically check whether an item is in stock 5.85 times a week on average. More than one in five say they make those checks more than ten times a week.

The findings point to a practical lesson for technology deployment: associates who participated in a pilot reported using most store tools at a rate of 74%, compared with 61% among those who were consulted before rollout and those who were never asked. Half of pilot participants reported high trust in their stock data, compared with 25% of those who were never asked for input.

Read The Store Truth Gap report here.

Asked what would make inventory management workflows easier, associates said responded with the following:

“Get the stock counts actually right so I’m not chasing ghost inventory.””A lot of times the back stock isn’t in the system so I go and have to physically check more often than I’d like.””More accurate layouts. Sometimes it sends me to a location that doesn’t have product.””More consultation from head office with us, who are the ones facing the customer.”

*Estimate is based on an average self-reported $18 hourly wage

About the survey

Scandit commissioned Sapio Research to survey 2,200 store associates online in September 2026. All worked in physical stores for retailers with more than 1,000 employees across the U.S., Germany, UK, France, Italy, Canada and Poland. The research covered grocery, mass merchant and department store, hypermarket and supercenter, DIY and home improvement, convenience, and drugstore and pharmacy formats.

About Scandit

Scandit is the leader in smart data capture, powered by vision AI, giving superpowers to workers, customers, and businesses by providing actionable insights and automating end-to-end processes. Its Smart Data Capture platform enables smart devices, such as smartphones, handheld computers, drones, digital eyewear, robots, and fixed cameras to interact with physical items by capturing data from barcodes, text, IDs, and objects with unmatched speed, accuracy, and intelligence.

Scandit enables innovation that delivers significant cost savings, increases employee retention and customer loyalty. The company partners with customers at every step with trials, solution design, integration, and customer success support included.

Visit scandit.com to learn why market leaders across retail, transport and logistics, healthcare and manufacturing like Instacart, Carrefour, Ahold Delhaize, Albertsons, Levi Strauss & Co., Sephora, Lufthansa, and FedEx trust Scandit.

 

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ai-plans-outrun-store-realities-as-bad-stock-data-can-cost-large-retailers-millions-each-year-302934596.html

Continue Reading

Trending